Clinical Trial Update: The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing single-dose and multi-dose pens of HRS9531 injection solution in adults with overweight/obesity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• HRS9531

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Overweight/Obesity | Phase 1 | Status: COMPLETED